Heptares' GPCR Platform Lands Cubist Collaboration
By Nuala Moran
Wednesday, January 9, 2013
Heptares Therapeutics Ltd. convinced another partner of the power of its G protein-coupled receptor (GPCR) technology, sealing a deal with Cubist Pharmaceuticals Inc. around one or possibly two targets to be nominated by the quoted U.S. biotech.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.